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Abstract: Background and Objectives: To investigate if pregnancies conceived using an oocyte donor
necessitate an alteration in immune regulation, we compared concentrations of insulin-like growth
factor binding protein (IGFBP)-1, insulin-like growth factor (IGF)-1 and T cell immunoglobulin
mucin-3 (Tim-3) in women with ongoing successful twin pregnancies conceived spontaneously,
using assisted reproductive technologies that utilized homologous oocytes or with donor oocytes.
Differences in levels of these immune modulatory proteins may be magnified and easier to detect
in twin as compared to singleton pregnancies. Methods: In this prospective study IGFBP-1 and
IGF-1 were measured in sera and Tim-3 in lysates of peripheral blood mononuclear cells (PBMCs)
by ELISA. Results: Median IGFBP-1 levels were lower in women with donor oocytes (41.4 ng/ml)
as compared to those with a spontaneous conception (51.2 ng/mL) or who conceived with various
assisted reproduction protocols using homologous oocytes (52.4 ng/mL) (p < 0.001). IGF-1 and Tim-3
levels were comparable in each group. The IGFBP-1 level was inversely correlated to the IGF-1
concentration only in women with donor oocytes (p = 0.032). IGFBP-1 and Tim-3 levels were similarly
negatively correlated in the donor oocyte group (p = 0. 012). Women in the assisted reproduction
group who conceived following intracytoplasmic sperm injection were the only other group in which
IGFBP-1 and Tim-3 were negatively correlated (p = 0.018). Conclusions: Down-regulation of IGFBP-1
production in pregnancies conceived with donor oocytes may reduce the extent of pro-inflammatory
immunity and contribute to successful outcome in totally allogeneic pregnancies.
Keywords: donor oocytes; insulin-like growth factor-1; insulin-like growth factor binding protein-1;
in vitro fertilization; pregnancy outcome; T cell immunoglobulin mucin-3
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1. Introduction
Pregnancies involving an oocyte donor differ from conventional gestations. In the absence of a
corpus luteum, the post-conception rise in estrogen and progesterone do not occur and these essential
hormones have to be exogenously supplied [1]. Additional compounds normally released from an
activated ovary also fail to be produced [2]. In conventional pregnancies, the maternal immune
system must respond to a fetus that expresses antigens derived from foreign paternal chromosomes
(semi-allogeneic). However, when fetuses are derived from fertilization of oocytes from a third-party
oocyte donor and then implanted in a second woman, both paternal and maternal antigens expressed
by the embryo are foreign. This places an additional burden on the maternal immune system to
effectively regulate the extent of reactivity to antigens from two exogenous sources. As a result,
immune-mediated placental pathology, has been shown to occur more frequently after pregnancy
with oocyte donors [3,4] and there is evidence of an increase in both pro- and anti-inflammatory
immune activity [5]. The most definitive study to date on maternal immune responses to donor oocytes
identified several differences from conventional pregnancies [6]. Cytokines levels in peripheral blood
and in the placenta are altered, and the number of activated T lymphocytes are elevated. As a probable
consequence of this elevated burden placed on the maternal immune system by the presence of a
totally allogeneic fetus the risk to develop preeclampsia is highest in donor oocyte gestations [7].
One mechanism that influences the magnitude of immune responses is an alteration in production
and/or activity of insulin-like growth factor binding protein-1 (IGFBP-1) and insulin-like growth
factor-1 (IGF-1). IGF-1 binds to cell surface receptors and induces the induction of pro-inflammatory
immunity [8]. IGFBP-1 competes for IGF-1 binding to cell surface receptors and down-regulates
IGF-1-directed inflammation [8]. In addition, IGFBP-1 produced in the decidua during the initiation of
embryo implantation [9] interacts with IGF-1 and facilitates placental development by regulating the
extent of trophoblast migration at the maternal-fetal interface [9]. IGFBP-1–IGF-1 interactions also
regulate the extent of fetal growth during early pregnancy [10,11].
Another mechanism to regulate immune activity is by the action of immune checkpoint inhibitors.
T cell immunoglobulin mucin 3 (Tim-3) is one such inhibitor located on the surface membrane of
activated T lymphocytes, macrophages/monocytes and natural killer cells [12–14]. Upon activation
Tim-3 suppresses pro-inflammatory immunity and thus, prevents prolonged immune activation [15].
During semi-allogeneic pregnancy, Tim-3 expression is up-regulated in peripheral blood cells [16] and
results in down-regulation of pro-inflammatory immunity at the maternal-fetal interface [17]. Both an
elevation or an inhibition in Tim-3 expression beyond optimal levels are associated with pregnancy
failure and spontaneous abortion [16–18].
In this communication, we evaluated whether variations in expression of IGFBP-1, IGF-1 and
Tim-3 and their interactions, differed between twin pregnancies that occurred spontaneously, resulted
from assisted reproductive technologies that utilized homologous oocytes or that employed donor
oocytes. We envisioned that changes in immune system regulation, perhaps difficult to observe in
singleton pregnancies, would be amplified and more readily demonstrable in multifetal pregnancies
due to the doubling of the number of fetuses.
2. Materials and Methods
2.1. Subjects
The study population in this prospective study consisted of 112 women with dichorionic diamniotic
twin pregnancies attending the outpatient obstetrics clinic at Careggi University Hospital in Florence
(Italy). Subjects were divided into three groups according to the mode of conception. Group 1 was
composed of 43 women with spontaneous conceptions; group 2 was 44 women who conceived by
assisted reproduction, either merely ovarian stimulation with clomiphene citrate (3), intrauterine
insemination (3), in vitro fertilization and embryo transfer (IVF-ET) (20), intracytoplasmic sperm
injection (ICSI) (18); group 3 was 25 women who were pregnant by IVF using oocyte donation.
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Samples were collected in mid-pregnancy, late second to early third trimester. Exclusion criteria
included the presence of a fetal malformation, pregnancy complication such as chronic hypertension,
diabetes, gestational hypertension, intra-uterine growth restriction of one or both fetuses, cholestasis
of pregnancy or inability to provide informed consent. The study was approved by the Institutional
Research Ethics Board at Careggi Hospital (30 May 2017, with number 10255_bio) and all subjects
provided informed written consent.
Following completion of the laboratory study demographic characteristics, medical and obstetrical
history, information regarding current pregnancy including gestational age at sample collection,
number of fetuses, complications during pregnancy (including presence of gestational diabetes and
use of betamethasone for fetal lung maturation) and gestational age at delivery were obtained by chart
review. Patient who had a preterm iatrogenic delivery were excluded from the gestational age at
delivery statistical analysis. Pregnancy dating was performed according to last menstrual period or
crown-rump length (CRL) recorded at ultrasound in the first trimester.
2.2. Assays
Blood samples were obtained from a peripheral forearm vein at the time of a routinely scheduled
check-up into a heparinized tube. Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque density gradient centrifugation, resuspended to a concentration of 5 million cells per
ml and 0.1 mL aliquots were immediately lysed in a detergent solution containing protease inhibitors,
as previously described [19]. The lysates were centrifuged and the supernatants were immediately
frozen in aliquots at −80 ◦C. Unheparinized blood was also obtained at the same time. The serum
fraction was collected by centrifugation and frozen in aliquots at −80 ◦C. All sera and PBMC lysates
were shipped in a single batch on dry ice to the Witkin lab for analysis. All samples remained frozen
during shipment. Thawed serum aliquots were assayed in duplicate for concentrations of IGFBP-1
and IGF-1 by commercial ELISA kits (R&D Systems, Minneapolis, MN, USA) by investigators blinded
to all clinical data. Similarly, Tim-3 in the lysates was measured by ELISA (R&D Systems). Values
were converted to ng/ml by reference to a standard curve that was generated in parallel to each assay.
The lower limit of sensitivity was 37 pg/mL for IGFBP-1, 31 pg/mL for IGF-1 and 8.8 pg/mL for Tim-3.
2.3. Data Analysis
All the continuous variables were checked for normality with the Shapiro-Wilk test and resulted
not-normally distributed. The non-parametric Kruskal-Wallis test was used to compare continuous
variables while the chi-square test was used to compare categorical variables. The Spearman rank
correlation test evaluated associations between IGF-1, IGFBP-1 and Tim-3. The statistical analysis was
performed using SPSS version 21.0. Differences were considered significant when the p value was <0.05.
3. Results
Characteristics of the study population are shown in Table 1. The women who conceived using
donor oocytes were significantly older than women in the other two groups (p < 0.001) and had the
lowest parity (p < 0.001). The median gestational age at sample collection, body mass index, use
of betamethasone for lung maturation, presence of gestational diabetes, gestational age at delivery,
delivery by cesarean section, the birthweight of both babies, smoking history and percent of White
race were comparable in all three groups.
The concentrations of IGFBP-1 and IGF-1 in the sera and Tim-3 in the PBMC lysates, from women
in the three groups are shown in Table 2. The median levels of IGF-1 and Tim-3 were comparable
regardless of the mode of conception and utilization of the mothers’ or donors’ oocytes. In contrast,
the median level of IGFBP-1 was significantly lower in women who were pregnant with donor oocytes
(p = 0.001). Individual values for all study subjects are shown in Figure 1. Similar values for all
three compounds were obtained when subjects in group two were separated by the specific assisted
Medicina 2019, 55, 144 4 of 7
reproduction technique that was performed (data not shown). There were no associations between the
serum IGFBP-1 level and maternal age, parity or time since initial sample collection in Italy.
Table 1. Characteristics of the study population.
Characteristic
Natural Conception Assisted Reproduction IVF-Donor Oocytes
n = 43 n = 44 n = 25
Age in years 34 (31–36) 35 (33–38.7) 42 (37–45) b
BMI (kg/m2) 21.1 (19.9–23.9) 21.4 (20.2–23.1) 23.3 (19.9–28.2)
Parity >0 51.2% 6.8% 4% b
Betamethasone 32.5% 31.8% 16%
Gestational Diabetes 18.6% 11.3% 28%
Cesarean section 97% 90% 95%
Gestational age sample a 24 (19–28) 19 (16–26) 21 (19–26)
Gestational age delivery a 37 (34–37) 37 (35.5–38) 36 (35–37)
Birthweight 1st baby 2430 (1930–2550) 2530 (2190–29,000) 2390 (1950–2662)
Birthweight 2nd baby 2290 (2140–2650) 2420 (2090–2710) 2230 (1867–2655)
Smoking 9.3% 0 4%
White race 93% 95.5% 96%
Numbers in parenthesis are standard deviation; a median (range) weeks; b p < 0.001; IVF: in vitro fertilization; BMI:
body mass index.
Table 2. Insulin-like growth factor binding protein-1 (IGFBP-1), insulin-like growth factor-1 (IGF-1) in
sera and T cell immunoglobulin mucin-3 (Tim-3) in peripheral blood mononuclear cells (PBMCs) from
women with twin pregnancies.
Group
Median (Range)
IGFBP-1 a IGF-1 a Tim-3 b
Spontaneous conception 51.2 (41.1–61.4) 2.4 (1.1–3.9) 201 (132–288)
Assisted reproduction 52.4 (39.3–61.7) 2.5 (1.4–4.5) 215 (159–263)
Donor oocytes 41.4 (24.2–48.6) c 2.7 (1.5–4.3) 197 (155–287)
a ng/mL; b pg/mL; c p = 0.001; IGFBP-1: Insulin-like growth factor binding protein-1; IGF-1: Insulin-like growth
factor-1; Tim-3: T cell immunoglobulin mucin-3.
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Associations between concentrations of IGFBP-1, IGF-1 and Tim-3 in each of the three subject
groups are shown in Table 3. Serum concentrations of IGF-1 and IGFBP-1 were negatively correlated
(Spearman r = −0.431, p = 0.032) only in women with pregnancies that utilized donor oocytes. The level
of IGFBP-1 in the circulation was also negatively associated with the Tim-3 concentration in PBMCs from
women in the donor oocyte group (Spearman r = 0.012, p = 0.012), as well as in the subpopulation of
women in the assisted reproduction group who became pregnant following ICSI (Spearman r = −0.552,
p = 0.018). There were no associations between Tim-3 and IGF-1 in any of the three groups.
Table 3. Associations between IGFBP-1, IGF-1 and Tim-3.
Pair Group Spearman r p Value
IGFBP-IGF-1
Spontaneous NS NS
Assisted reproduction NS NS
Donor oocytes −0.431 0.032
IGFBP-1-Tim-3
Spontaneous NS NS
Assisted reproduction a −0.552 0.018
Donor oocytes −0.495 0.012
IGF-1-Tim-3
Spontaneous NS NS
Assisted reproduction NS NS
Donor oocytes NS NS
a This association was confined to the subgroup of women who underwent ICSI followed by IVF. There was no
association between IGFBP-1 and Tim-3 in the other subgroups of women in this group. NS: not significant
4. Discussion
We identified a reduction in the concentration of IGFBP-1 in the circulation of women with
twin pregnancies derived from donor oocytes as compared to IGFBP-1 levels in women with twin
pregnancies from spontaneous conceptions or from assisted reproduction technologies that utilized
homologous oocytes. This finding is consistent with a previous report of reduced serum IGFBP-1
levels in singleton ovum donor-related pregnancies [1]. In the singleton study, it was suggested that
an absence of ovarian stimulation in women with donor oocytes resulted in a loss of IGFBP-1 and/or
IGFBP-1 inducers that would normally be released from ovarian tissues in gestation. We further show
that the IGFBP-1 level is inversely correlated to the IGF-1 level only in those twin pregnancies that
employed donor oocytes and that IGFBP-1 and Tim-3 concentrations are also inversely correlated in
women who employed donor oocytes.
IGFBP-1 interacts with IGF-1 and reduces its bioavailability [11]. The strong negative association
between serum levels of these two compounds only in twin pregnancies that utilized an oocyte donor
suggests that a similar relationship might also exist at the maternal-fetal interface. This would result
in a more stringent control over trophoblast migration, placental development, pro-inflammatory
immune activation and the rate of fetal growth than would occur in semi-allogeneic pregnancies. In
pregnancies with homologous oocytes, there may be less of a need for a more precise coordination of
IGFBP-1 and IGF-1 production, due, perhaps, to the presence of additional immune regulatory factors
emanating from the ovary. The negative association between serum IGFBP-1 and Tim-3 expression
on PBMCs also supports the occurrence of unique regulatory mechanisms that coordinate immune
activity in twin gestations derived from donor oocytes.
We also observed a negative association between IGFBP-1 and Tim-3 levels in women who became
pregnant via ICSI but not in those who utilized IVF-ET. This suggests that the state of the ovary,
in addition to regulating IGFBP-1 production, may also exert an influence on Tim-3 expression on
lymphoid cells. The assisted penetration of the oocyte by the sperm may induce changes in properties
of fertilized ova that influence immune checkpoint inhibitor expression during pregnancy. This
unexpected observation deserves further study.
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Our study has several limitations. Serum pro- or anti-inflammatory cytokines were not measured
and so there is no direct evidence relating the IGFBP-1 concentration to the cytokine level in the
circulation of women with donor oocyte-related pregnancies. While it would have been advantageous
to include these measurements, their analysis would not necessarily directly relate to the state of
immunity at the maternal-fetal interface which differs from that present in the peripheral circulation [6].
In addition, other possible influences on immune regulation such as circulating levels of insulin [20] or
IGF-2 [21] were not evaluated in our study. Although we did utilize a control group that underwent IVF
using homologous oocytes, it cannot be definitively ruled out that conditions unique to the collection,
incubation and transfer of donor oocytes had an unknown effect on IGFBP-1 production. Another
limitation is the smaller number of women in the donor oocyte group compared to subjects in the
other groups. However, we wish to stress that an immune evaluation of women with multifetal
gestations who conceived using donor oocytes has not been reported previously to our knowledge
and so dissemination of our findings, although not definitive, is hopefully of sufficient interest to
spur additional investigations in this area. It should be noted that our study was confined to women
with successful ongoing pregnancies and deliveries. Whether deviations from these relationships are
associated with failed donor oocyte-related pregnancies remain to be determined.
Age and parity are significantly different in the oocyte recipient group compared to others. These
two variables could have influenced the levels of IGFBP-1 and this is a limitation of the study; however,
this is an invariable issue with IVF studies, since IVF patients are usually older and nullipara, compared
to spontaneous conception patients, who usually are younger and multipara.
5. Conclusions
In conclusion, compared to those with twin gestations derived from their own oocytes, women
with twin pregnancies conceived using donor oocytes have reduced circulating levels of IGFBP-1 and
the concentration of IGFBP-1 is coordinated with levels of IGF-1 and Tim-3.
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